TY - JOUR
T1 - Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma
AU - Harris, A.
AU - Spaeth, G. L.
AU - Sergott, R. C.
AU - Katz, L. J.
AU - Cantor, L. B.
AU - Martin, B. J.
N1 - Funding Information:
From the Department of Ophthalmology (Drs. Harris and Cantor) and the Department of Physiology and Biophysics, Indiana University Medical Center, Indianapolis, Indiana (Dr. Harris); Neuro-ophthalmology Service, Wills Eye Hospital, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania (Drs. Spaeth, Sergott, and Katz); and Medical Sciences Program, Indiana University, Bloomington, Indiana (Dr. Martin). This study was supported in part by Alcon Laboratories, Inc., Fort Worth, Texas, grant 10180-01 from the National Institutes of Health, Bethesda, Maryland, and an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York.
PY - 1995
Y1 - 1995
N2 - PURPOSE: β-Adrenergic blocking drugs lower intraocular pressure. The question of whether these drugs also alter, either directly or indirectly, orbital hemodynamics is potentially of great importance for patients with normal-tension glaucoma who may have some degree of reversible vasospasm. METHODS: We compared the effect of selective (betaxolol) and nonselective (timolol) β-adrenergic blocking drugs on flow velocities (as determined by color Doppler imaging) in orbital vessels in 13 patients with normal-tension glaucoma (mean age, 62 ± 3 years; mean intraocular pressure, 15 ± 2 mm Hg). A one-month drug treatment double-masked crossover design, with a three-week washout before each drug, was used. RESULTS: Neither drug changed peak systolic velocity in any of the four vessels studied (ophthalmic, nasal and temporal posterior ciliary, and central retinal arteries). Additionally, timolol did not alter end-diastolic velocity or resistance index (defined as [peak systolic velocity minus end-diastolic velocity] divided by peak systolic velocity) in any of the vessels measured. In contrast, betaxolol tended to increase end-diastolic velocity and to decrease resistance index: the four-vessel average end-diastolic velocity increased 30% (P = .08), and the four-vessel average resistance index decreased significantly (P = .04). These reductions in resistance index occurred despite that betaxolol, in contrast to timolol, did not significantly decrease intraocular pressure. CONCLUSIONS: These results suggest that, in patients with normal-tension glaucoma, selective β-adrenergic blockade (betaxolol) may have ocular vasorelaxant effects independent of any influence on intraocular pressure, whereas nonselective blockade (timolol) lowers intraocular pressure without apparently altering orbital hemodynamics.
AB - PURPOSE: β-Adrenergic blocking drugs lower intraocular pressure. The question of whether these drugs also alter, either directly or indirectly, orbital hemodynamics is potentially of great importance for patients with normal-tension glaucoma who may have some degree of reversible vasospasm. METHODS: We compared the effect of selective (betaxolol) and nonselective (timolol) β-adrenergic blocking drugs on flow velocities (as determined by color Doppler imaging) in orbital vessels in 13 patients with normal-tension glaucoma (mean age, 62 ± 3 years; mean intraocular pressure, 15 ± 2 mm Hg). A one-month drug treatment double-masked crossover design, with a three-week washout before each drug, was used. RESULTS: Neither drug changed peak systolic velocity in any of the four vessels studied (ophthalmic, nasal and temporal posterior ciliary, and central retinal arteries). Additionally, timolol did not alter end-diastolic velocity or resistance index (defined as [peak systolic velocity minus end-diastolic velocity] divided by peak systolic velocity) in any of the vessels measured. In contrast, betaxolol tended to increase end-diastolic velocity and to decrease resistance index: the four-vessel average end-diastolic velocity increased 30% (P = .08), and the four-vessel average resistance index decreased significantly (P = .04). These reductions in resistance index occurred despite that betaxolol, in contrast to timolol, did not significantly decrease intraocular pressure. CONCLUSIONS: These results suggest that, in patients with normal-tension glaucoma, selective β-adrenergic blockade (betaxolol) may have ocular vasorelaxant effects independent of any influence on intraocular pressure, whereas nonselective blockade (timolol) lowers intraocular pressure without apparently altering orbital hemodynamics.
UR - http://www.scopus.com/inward/record.url?scp=0029164594&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(14)72604-2
DO - 10.1016/S0002-9394(14)72604-2
M3 - Article
C2 - 7639300
AN - SCOPUS:0029164594
SN - 0002-9394
VL - 120
SP - 168
EP - 175
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 2
ER -